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Polybrominated diphenyl ethers (PBDEs) are
widely used as ﬂame retardants, and the gen-
eral population is exposed through products
such as upholstery, building materials, insula-
tion, electronic equipment, and contaminated
food. PBDEs are added to polymers without
being chemically bound and can leach into
the environment, where they settle with air
particles and sludge. They are persistent, and
some—BDE-47, BDE-99, and BDE-153—
can accumulate in lipid-rich tissues (Agency
for Toxic Substances and Disease Registry
2004; Sjödin et al. 2003).
Concentrations of PBDE in human
European breast milk samples are generally
low compared with those in the United
States, and considered to be well below the
estimated lowest observed adverse effect level
(LOAEL) of 1 mg/kg/day (Darnerud et al.
2001). Two technical mixtures, penta- and
octa-mixtures of PBDEs, have been banned
from use in Europe since 2003 (Darnerud
et al. 2001), and Swedish studies indicated a
decrease in breast milk levels since the middle
of the 1990s (Meironyte et al.1999; Sjödin
et al. 2003). However, annual production
rates of some PBDEs are still considerable in
some areas (Alaee et al. 2006; Betts 2002;
Law et al. 2006). Animal studies show that
some PBDEs exhibit endocrine-disrupting
activity, which has been studied predomi-
nantly for thyroid hormone transport and
metabolism (Legler and Brouwer 2003), but
data on adverse effects on reproductive out-
come after gestational exposure are also
emerging (Lilienthal et al. 2006).
The prevalence of cryptorchidism in new-
born boys appears to have increased in some
areas, such as Great Britain and Denmark,
over the past decades, and its current preva-
lence is considerably higher in Denmark than
in Finland (Anonymous 1986; Boisen et al.
2004). Although the reason for this is as yet
unknown, the rapid increase in prevalence
suggests that environmental factors are
involved (Sharpe 2006; Skakkebæk et al.
2001). Adverse effects of fetal exposure to
environmental chemicals on testicular descent
and hormonal function may be detectable
during the short physiologic activation of the
pituitary–gonadal axis at approximately
3 months of age (Andersson et al. 1998;
Main et al. 2000, 2006b; Suomi et al. 2006).
In this study we aimed to evaluate the asso-
ciation between exposure to 14 PBDEs (BDEs
28, 47, 66, 71, 75, 77, 85, 99, 100,119, 138,
153, 154, 183) in newborn boys and the posi-
tion and function of the testes.
Materials and Methods
The study was conducted according to the
Helsinki II Declaration (World Medical
Association 2000) after informed oral and
written consent of the parents. The ethical
committees (Finland: 7/1996; Denmark:
KF01-030/97) and the Danish Data
Protection Agency (1997-1200-074) approved
the study.
Study population. We obtained breast
milk samples and placentas from a joint
prospective, longitudinal cohort study per-
formed 1997–2001 at Turku University
Hospital, Turku, Finland, and the National
University Hospital (Rigshospitalet, Hvidovre
Hospital), Copenhagen, Denmark. This
binational study aimed at establishing con-
temporary prevalence rates for cryptorchidism
and hypospadias and evaluating risk factors
by means of questionnaires and biological
samples (blood, placentas, breast milk).
Exposure measurements were prospectively
planned to include persistent and nonpersis-
tent chemicals, some of which have been pre-
viously reported (Damgaard et al. 2006;
Main et al. 2006a; Shen et al. 2005, 2006,
2007). Recruitment strategy, inclusion crite-
ria, and clinical examination of the children
(i.e., the identification of cryptorchidism)
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BACKGROUND: Polybrominated diphenyl ethers (PBDEs) are widely used in Western countries.
OBJECTIVES: Because the prevalence of cryptorchidism appears to be increasing, we investigated
whether exposure to PBDEs was associated with testicular maldescent.
METHODS: In a prospective Danish–Finnish study, 1997–2001, all boys were examined for cryp-
torchidism. We analyzed whole placentas (for 95 cryptorchid/185 healthy boys) and individual
breast milk samples (62/68) for 14 PBDEs and infant serum samples for gonadotropins, sex-hor-
mone binding globulin, testosterone, and inhibin B.
RESULTS: In 86 placenta–milk pairs, placenta PBDE concentrations in fat were lower than in breast
milk, and a larger number of congeners were nondetectable. There was no signiﬁcant difference
between boys with and without cryptorchidism for individual congeners, the sum of 5 most preva-
lent, or all 14 congeners. The concentration of PBDEs in breast milk was signiﬁcantly higher in
boys with cryptorchidism than in controls (sum of BDEs 47, 153, 99, 100, 28, 66, and 154:
median, 4.16 vs. 3.16 ng/g fat; p < 0.007). There was a positive correlation between the sum of
PBDEs and serum luteinizing hormone (p < 0.033). The sum of PBDEs in breast milk did not dif-
fer between Denmark and Finland (median, 3.52 vs. 3.44 ng/g fat), but signiﬁcant differences in
some individual congeners were found.
CONCLUSIONS: Two different proxies were used for prenatal PBDE exposure, and levels in breast
milk, but not in placenta, showed an association with congenital cryptorchidism. Other environ-
mental factors may contribute to cryptorchidism. Our observations are of concern because human
exposure to PBDEs is high in some geographic areas.
KEY WORDS: breast milk, cryptorchidism, exposure, human, infant, polybrominated diphenyl
ethers. Environ Health Perspect 115:1519–1526 (2007). doi:10.1289/ehp.9924 available via
http://dx.doi.org/ [Online 31 May 2007]have been previously described (Boisen et al.
2004; Main et al. 2006b; Suomi et al. 2006)
and were strictly standardized. Boys with nor-
mally descended testes, including retractile
testes, were used as controls in this study
under the terms “controls” or “healthy boys.”
Boys with undescended testes (nonpalpable,
inguinal, suprascrotal, high scrotal), either
uni- or bilaterally at birth, were included in
the group of cryptorchid boys.
All boys were examined at birth and at
3 months of age before the results of chemical
analyses were known. Birth weight and length
were obtained from hospital records. The
supine length of the children was measured
with infantometers (Denmark: Kidimeter,
Raven Equipment Ltd., Essex, United
Kingdom; Finland: Pedihealth Ky, Oulu,
Finland). Weight was measured on a digital
scale (Baby scale model; Solotop Oy,
Helsinki, Finland). Weight for gestational age
was calculated using national standards as per-
cent deviation from the expected mean
(Marsál et al. 1996; Pihkala et al. 1989),
–22% being equivalent to –2 SDs.
Biological samples. In Denmark biological
samples were collected from all participants
(case–cohort design). In Finland, due to lack of
storage space, biological samples were collected
from boys with cryptorchidism at birth and
matched controls [matching criteria: parity,
maternal smoking (yes/no), diabetes (yes/no),
gestational age (± 7 days), and date of birth
(± 14 days)] as a nested case–control design.
From this bio-bank, we selected 280 pla-
centas (168 Danish/112 Finnish) and 130
breast milk samples (65 Danish/65 Finnish)
for PBDE measurements; this number was
determined by funding. Birth examination
data were used for classification of cryp-
torchid and healthy boys.
In Finland, placentas were selected from
56 case–control pairs, in which both placentas
were available. In Denmark, all available pla-
centas from cryptorchid boys were chosen (n =
39). Control placentas were selected randomly
from the total Danish cohort (n = 129).
Hereafter, 65 breast milk samples were
selected for each country, with the aims, if
possible, of having equal numbers of samples
from boys with and without cryptorchidism
and of including the same mothers as for pla-
centa analyses. Only samples with a volume
> 125 mL were included to ensure that all
chemicals could be analysed. Milk from
mothers of 29 cryptorchid boys and 36 ran-
domly chosen control boys was included in
Denmark. In Finland, milk samples were
chosen from mothers of cryptorchid boys (n =
33), matched controls (n = 18), or random
controls (n = 14).
For 86 boys, milk and placentas could be
selected from the same mother–child pair (10
Danish boys with cryptorchidism, 33 Danish
controls, 20 Finnish boys with cryp-
torchidism, 23 Finnish controls).
Collection of samples. Whole placentas
were collected by the midwives and frozen
immediately in two layers of polyethylene
bags (–20°C). Placentas were not bled
before storage.
Each mother collected one breast milk
sample. We wished to assess the average con-
centration of PBDEs during the period pre-
ceding the endogenous hormone surge in
infants. Thus, each sample consisted of sev-
eral small aliquots collected over successive
feedings over several weeks and frozen in
household freezers in 250-mL Pyrex glass bot-
tles (1515/06D; Bibby Sterilin, Staffordshire,
UK) with Teflon coated caps. The mothers
were instructed orally and in writing to feed
the baby, and then to sample aliquots (hind
milk), beginning 1 month after birth. We
chose this start point after discussion with the
ethics committee for human subject studies to
ensure that breast-feeding had been well
established. Mothers were instructed to col-
lect samples into a clean household glass or
porcelain container, avoiding, if possible, the
use of breast pumps, and to freeze every por-
tion immediately. Breast milk was delivered
frozen to the hospital at the 3 months’ exami-
nation and stored at –20°C. In 57 of the 65
Danish mothers, but no Finnish mothers,
information on breast pump use was obtained
at sample delivery; 26 (46%) had used a
pump on one or more occasions. No informa-
tion was obtained on the type of breast pump
(glass or plastic).
Blood samples. Venous nonfasting blood
samples (4 mL) were drawn from the infants
at the 3 months’ examination (median age,
3.0 months; range, 2.4–4.1); the overall suc-
cess rate of obtaining a sample in the study
was 74%. After clotting, the blood samples
were centrifuged and the sera were separated
and stored at –20°C. All samples were
analysed as duplicates and blinded for the
technician at one laboratory (Rigshospitalet,
Denmark) for reproductive hormones. Each
run contained samples of both cryptorchid
and healthy boys from both countries (up to
160 samples per analysis) to minimize any
effect of interassay variation.
Hormone analyses. We analyzed serum
follicle-stimulating hormone (FSH), luteiniz-
ing hormone (LH), and sex hormone–bind-
ing globulin (SHBG) using time-resolved
immunofluorometric assays (Delfia, Wallac
Inc., Turku, Finland). Detection limits were
0.06 and 0.05 IU/L for FSH and LH, respec-
tively, and 0.23 nmol/L for SHBG. The
intra- and interassay coefficients of variation
(CV) were < 5% in both gonadotropin assays
and < 6% for SHBG. We measured serum
testosterone by radioimmunoassay (Coat-a-
Count; Diagnostic Products Corp., Los
Angeles, CA, USA), with a detection limit of
0.23 nmol/L and intra- and interassay CVs
< 10%. Free testosterone index was calcu-
lated: (testosterone × 100)/SHBG. We ana-
lyzed serum inhibin B by a double antibody
enzyme-immunometric assay (Main et al.
2006b). The detection limit was 20 pg/mL,
and intra- and interassay CVs were < 15 %
and < 18 %, respectively. Ratios between hor-
mones were calculated: LH/testosterone,
LH/free testosterone, FSH/inhibin B.
Analysis of PBDE. All PBDE analyses for
both milk and placenta were performed at the
laboratory at the Department of Environ-
mental Health in Kuopio, Finland. Placentas
were defrosted, and the umbilical cord and all
readily removable membranes were discarded.
Whole placentas were homogenized in a mixer
(Büchi Mixer B-400; Büchi Laboratories AG,
Flawil, Switzerland), and 75 g of the
homogenate was lyophilized. Dried homo-
genate was pulverized in a mortar and slurry
was made by adding dichloromethane and
cyclohexane (1:1 vol/vol) and concentrated sul-
phuric acid. This slurry was spiked with six
13C-labeled PBDE internal standards (BDEs
28, 47, 77, 99, 153, and 183) (Wellington
Laboratories Inc., Guelph, Canada). Fat was
not determined, and fat-based results were
relying on the gravimetrically measured fat
contents obtained from a German partner in
this European Commission project (Shen et al.
2005, 2006, 2007).
Breast milk samples (average volume,
70 mL) were thawed in sample bottles in a
water bath (40°C) for 1 hr and homogenized.
Fat was extracted with a mixture of diethyl
ether and hexane (1:1.4 vol/vol) after addition
of sodium oxalate solution and ethanol
(1:5 vol/vol). Fat content was determined
gravimetrically after exchange of the solvent
to hexane. An average 1.5 g of fat was spiked
with the same set of internal standards used
with placenta.
The procedure for decomposition of fat
and sample cleanup has been described previ-
ously (Kiviranta et al. 2004). We quantified
14 PBDE analytes (BDEs 28, 75, 71, 47, 66,
77, 100, 119, 99, 85, 154, 153, 138, and
183) by selective-ion recording using a high
resolution mass spectrometer (Autospec
Ultima; Micromass Inc., Manchester, UK) at
resolution 10,000. Gas chromatographic sep-
aration of the PBDEs was performed with a
Hewlett Packard 6890 gas chromatograph
with fused silica capillary column (DB5-MS,
60 m, 0.25 mm, 0.25 µm; J&W Scientific,
Folsom, CA, USA). As a recovery standard
for internal PBDE standards polychlorinated
biphenyl congener 159 was used.
In the analysis of PBDEs at the
Department of Environmental Health
(National Public Health Institute, Kuopio,
Finland), the technicians and chemists were
Main et al.
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ination was monitored by analyzing proce-
dural blank samples. The concentrations of
these blank samples were much lower than the
concentrations in placenta and breast milk—
on average, 3.6 and 2.6% of the average sum
of PBDEs in placenta and milk, respectively.
Recoveries of individual internal PBDE
standards were > 60%. Median limit of quan-
tiﬁcation (LOQ) for placentas corresponding
to a signal to noise ratio of 3:1, was 0.006
ng/g fat (range, 0.004–0.14 ng/g fat).
Corresponding LOQs for breast milk were
0.004 ng/g fat (range, 0.0003–0.12 ng/g fat).
In placenta, CVs for individual congeners were
10–20%, and > 20% at concentration levels
0.1–1 ng/g fat and < 0.1 ng/g fat, respectively.
In breast milk samples corresponding values
were < 10%, 10–20%, and > 20% at concen-
trations levels > 1 ng/g fat, 0.1–1 ng/g fat, and
< 0.1 ng/g fat, respectively. Concentrations
below the LOQ were considered to be equal to
nil (lower bound results). The laboratory has
successfully participated in interlaboratory
comparison studies of PBDEs in different bio-
logical matrices including breast milk (Becher
et al. 2001; Småstuen and Becher 2004;
Småstuen and Becher 2005). The Finnish
Accreditation Service (FINAS; Espoo, Finland)
has veriﬁed the competence of the laboratory
(testing laboratory T077) in performing PBDE
analyses in biological samples according to the
European Standard (EN ISO/IEC 17025).
Statistics
Population characteristics are given as medians
and percentiles (2.5th, 97.5th). Differences
between boys with and without cryp-
torchidism and between Danish and Finnish
populations were analysed by Mann-Whitney
U-test. Eighty-six boys participated with both
breast milk and placenta samples.
We tested country differences for (log-
transformed) PBDE concentrations in breast
milk and placenta by multiple linear regres-
sion including maternal age, parity (1, 2 and
≥ 3) and prepregnancy body mass index
(BMI; kilograms per square meter) in
the model.
Correlations between individual PBDE
congener concentrations, and between PBDE
concentrations and date of childbirth within
the Danish and Finnish cohort, respectively,
were tested by Spearman correlation on non-
transformed data. For each country the date of
birth for the ﬁrst child was set at zero; the date
of birth for all consecutive children was then
calculated as number of days elapsed since the
ﬁrst child of the same country-speciﬁc cohort.
This variable was applied to control for any
time trends in ﬂame-retardant concentration
in the study period 1997–2001.
We tested differences in PBDE concentra-
tions between boys with and without cryp-
torchidism in a multiple regression model,
including as covariates maternal age, parity,
maternal prepregnancy BMI, and date of
childbirth within the cohort (days) to control
for factors that could affect PBDE concentra-
tions in the sample. Prematurity and small
size for gestational age (SGA) are well-known
risk factors for cryptorchidism. Because the
number of premature (5 Danish, 3 Finnish)
and SGA children (3 Danish, 1 Finnish) was
small in this study, analyses were carried out
both with and without inclusion of these
parameters. Analyses were carried out only for
the most abundant seven congeners in breast
milk (and their sum) and for the most abun-
dant ﬁve congeners in placenta.
We used multiple linear regression analysis
to assess the correlation between serum levels
of reproductive hormones (log-transformed
LH, FSH, SHBG, inhibin B), square root–
transformed serum testosterone or free testos-
terone index, and log-transformed PBDE
concentrations in breast milk. Covariates
included in these analyses were country of
origin, testicular position (cryptorchidism/
control), and age at blood sampling (months).
Results
There were no signiﬁcant differences in mater-
nal age, reported smoking, and parity between
cryptorchid and control boys (Tables 1 and 2).
Gestational age and birth weight were slightly
lower in cryptorchid Danish (but not Finnish)
boys than in controls. Diabetes was more
prevalent in Finnish (but not Danish) mothers
of cryptorchid boys than in their controls,
because we could not always find controls
matched by this criterion. The date of child-
birth within the study period did not differ
significantly between cryptorchid boys
and controls (Denmark, p = 0.327; Finland,
p = 0.949).
Danish mothers were slightly older than
Finnish [30.6 years; 95% conﬁdence interval
(CI), 23.6–38.8 vs. 28.7 years; 95% CI,
21.4–39.7; p < 0.011], had a lower parity (p <
0.033) and smoked more frequently (p < 0.04).
The prevalence of diabetes mellitus was higher
among Finnish women (p < 0.004), but BMI
before pregnancy (p = 0.678) did not differ sig-
niﬁcantly between the countries (p = 0.225).
Breast milk. Seven PBDEs were measur-
able in all breast milk samples (Table 3).
Median concentrations were higher in Danish
but not Finnish cryptorchid boys than in con-
trols, reaching statistical signiﬁcance for BDEs
47, 100, 28, 66, and 154. The sum of all seven
congeners was significantly higher in cryp-
torchid boys than in controls if both countries
were analyzed together (p < 0.007) (Figure 1),
also if prematurity and SGA were included in
the model (p < 0.035). Similar results were
obtained for PBDE expressed as nanograms
per liter (data shown only for the sum of all
14 congeners; Table 3). Table 4 shows the
remaining seven congeners, which were below
the detection limit in a substantial number of
samples, and the sum of all 14 congeners.
Flame retardants and cryptorchidism
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Table 1. Population characteristics [median (2.5th–97.5th percentiles)] for breast milk samples.
Denmark Finland
Characteristic Control (n = 36) Cryptorchid (n = 29) p-Value* Control (n = 32) Cryptorchid (n = 33) p-Value*
Maternal age (years) 29.8 (23.0 to 42.6) 29.8 (25.8 to 39.2) 0.979 27.7 (19.9 to 38.5) 29.7 (21.5 to 39.9) 0.306
BMI (kg/m2)a 22.9 (19.1 to 31.6) 23.0 (17.9 to 30.5) 0.997 22.8 (18.4 to 35.6) 22.0 (18.2 to 27.9) 0.106
Diabetes (yes/no) 1/35 1/28 0.877 0/32 4/29 0.044
Smoking (yes/no) 9/27 7/22 0.937 4/28 6/27 0.529
Parity (no.)
1 28 20 0.451 19 17 0.405
24 5 9 9
≥ 34 4 4 7
Gestational age (days) 284 (253 to 297) 278 (219 to 296) 0.039 280 (160 to 296) 281 (249 to 296) 0.768
WGA (%) 1.89 (–23.5 to 35.6) 0.62 (–29.7 to 30.5) 0.687 –1.59 (–21.9 to 20.0) 1.17 (–30.8 to 27.3) 0.451
Birth weight (kg) 3.73 (2.65 to 5.15) 3.52 (1.31 to 4.85) 0.139 3.46 (2.86 to 4.46) 3.83 (2.51 to 4.66) 0.397
Birth length (cm) 53 (48 to 57) 52 (35 to 59) 0.264 51 (47 to 55) 52 (46 to 55) 0.826
Cryptorchidism at 3 months (no.) — 4 — — 25 —
Prematurity (no.)b 14 — 21 —
SGA (no.) 1 2 — 0 1 —
Infant blood samples (no.) 21 24 25 26
WGA, weight for gestational age.
aMaternal prepregnancy BMI. b< 259 days of gestation. *Difference between cryptorchid boys and controls.The concentrations of PBDE congeners
in milk samples showed large variations
between congeners and individuals (Figure 2).
Individual congener concentrations were pos-
itively correlated with one another (r =
0.178–0.955, p < 0.0001).
There were no signiﬁcant country differ-
ences in the sum of all congeners [Denmark,
3.52 ng/g (95% CI, 1.26–14.2) vs. Finland,
3.44 ng/g (95% CI, 1.25–13.94), p = 0.754]
or the sum of the most prevalent seven con-
geners, BDEs 47, 153, 99, 100, 28, 66, and
154 [Denmark, 3.24 ng/g (95% CI,
1.26–51.1) vs. Finland, 3.23 ng/g (95% CI,
1.26–51.0), p = 0.629]. Similar results were
obtained if we analyzed only milk samples
from mothers of healthy boys (data not
shown). The estimated daily intake of PBDEs
(sum of all) for an infant at 3 months of age
(median infant body weight 6.58 kg, consum-
ing 120 mL breast milk/kg) was a median of
16 ng/kg/day (range, 6–121 ng/kg/day).
Breast milk lipid (percent wet weight) differed
significantly between the countries (mean ±
SD = 2.99 ± 1.38 in Denmark, 4.52 ± 1.56 in
Finland; p < 0.0001). The lipid content was
not significantly correlated with the sum of
PBDE congeners (data not shown).
The pattern of congener distribution
differed between the countries. BDE-28 was
significantly higher in Finland than in
Denmark (p < 0.021), with a similar tendency
for BDE-47 (p < 0.077), which was the most
prevalent congener. BDE-153 (p < 0.0001),
BDE-66 (p < 0.026), and BDE-183 (p <
0.022) were signiﬁcantly higher in Denmark
than in Finland, with a similar tendency for
BDE-99 (p < 0.073). For congeners at very
low concentrations, the percentage of measur-
able samples was higher in Denmark than in
Finland (Table 4). There was no significant
effect of breast pump use during collection of
samples on the concentration of any BDE
congener in the Danish breast milk samples.
In the Danish but not the Finnish sam-
ples, the date of childbirth within the cohort
was signiﬁcantly correlated with the concen-
tration of BDE-154 (r = –0.346, p < 0.005),
BDE-85 (r = –0.434, p < 0.0001) and
BDE-75 (r = 0.376, p < 0.002) with similar
tendencies for BDE-66 (r = –0.211, p =
0.092) and BDE-77 (r = –0.214, p = 0.087).
Serum LH levels correlated positively with
the sum of seven PBDEs in breast milk (r =
0.218, p < 0.033) as well as with individual
congeners BDE-47 (r = 0.227, p < 0.027),
BDE-100 (r = 0.293, p < 0.004), and
BDE-154 (r = 0.203, p < 0.048). Country-
specific analyses showed significant associa-
tions between serum LH and the above listed
PBDEs and their sum for Finnish milk sam-
ples, but not Danish (data not shown). No
other reproductive hormones or their ratios
were signiﬁcantly correlated with the concen-
tration of PBDEs.
Placentas. The average levels of 14 PBDE
congeners per gram fat in placentas were
lower than in breast milk (Table 5), and more
samples were nondetectable. Therefore, the
sum of ﬁve congeners was used instead of the
seven congeners used for milk. This had a
minor influence on the total, because the
sums of the five and the 14 congeners were
very close.
The distribution of congeners resembled
the distribution in breast milk, with BDE-47
and BDE-153 constituting the main fraction
of PBDEs. There was no significant country
difference for the sum of all 14 congeners (p =
0.198) or the sum of ﬁve (BDE-47, BDE-153,
BDE-99, BDE-100, and BDE-28; p = 0.192).
This was also true when only placentas from
healthy boys were analyzed (data not shown).
The concentrations of the ﬁve most prevalent
congeners were positively correlated with each
other (r = 0.171–0.827, p < 0.0001). Placenta
lipid content (percent wet weight) differed sig-
niﬁcantly between the countries (mean ± SD =
1.09 ± 0.17 in Denmark, 1.21 ± 0.13 in
Finland; p < 0.0001). Placenta lipid content
Main et al.
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Table 2. Population characteristics [median (2.5th–97.5th percentiles)] for placentas.
Denmark Finland
Characteristic Control (n = 129) Cryptorchid (n = 39) p-Value* Control (n = 56) Cryptorchid (n = 56) p-Value*
Maternal age (years) 31.0 (22.7 to 38.5) 29.5 (25.7 to 45.7) 0.723 28.1 (20.6 to 38.1) 29.1 (20.1 to 42.2) 0.349
BMI (kg/m2)a 22.1 (18.2 to 35.5) 21.5 (17.8 to 36.1) 0.199 22.3 (17.8 to 31.7) 23.1 (17.8 to 37.5) 0.062
Diabetes (yes/no) 2/127 0/39 0.435 0/55 10/46 0.001
Smoking (yes/no) 32/91 11/28 0.788 9/47 4/48 0.793
Parity (no.)
1 81 26 0.628 31 31 0.997
23 6 1 0 1 9 1 9
≥ 31 2 3 6 6
Gestational age (days) 283 (254 to 298) 276 (195 to 294) 0.001 280 (255 to 293) 280 (258 to 303) 0.940
WGA (%) 0.29 (–23.3 to 34.9) –0.83 (–39.5 to 44.4) 0.921 –0.32 (–21.7 to 25.7) –1.12 (–27.9 to 25.0) 0.895
Birth weight (kg) 3.63 (2.49 to 5.06) 3.45 (0.75 to 4.75) 0.038 3.54 (2.85 to 4.61) 3.63 (2.55 to 4.58) 0.807
Birth Length (cm) 53 (47 to 57) 52 (32 to 60) 0.230 51 (47 to 55) 51 (48 to 55) 0.955
Cryptorchidism at 3 months (no.) — 8 — — 33 —
Prematurity (no.)b 66 — 3 1 —
SGA (no.) 5 2 — 0 3 —
Infant blood samples (no.) 88 25 45 35
WGA, weight for gestational age.
aMaternal prepregnancy BMI. b< 259 days of gestation. *Difference between cryptorchid boys and controls.
Table 3. Seven PBDEs, detectable in all breast milk samples from Danish and Finnish boys with and without cryptorchidism [median (2.5th–97.5th percentiles)].
PBDE congener Denmark Finland Both countries
(ng/g fat) Control (n= 36) Cryptorchid (n= 29) p-Value* Control (n= 32) Cryptorchid (n= 33) p-Value* Control (n= 68) Cryptorchid (n= 62) p-Value*
Sum of 7 congeners 3.21 (1.09–9.07) 4.12 (1.34–18.78) 0.017 3.08 (1.04–29.17) 4.27 (1.43–56.30) 0.111 3.16 (1.08–21.47) 4.16 (1.39–51.62) 0.007
47 1.05 (0.45–3.63) 1.53 (0.34–11.7) 0.018 1.24 (0.4–15.20) 1.82 (0.65–38.90) 0.062 1.12 (0.42–12.87) 1.56 (0.45–33.13) 0.003
153 1.0 (0.31–3.35) 1.18 (0.64–3.14) 0.226 0.67 (0.22–2.97) 0.68 (0.27–3.63) 0.394 0.81 (0.28–3.08) 0.94 (0.33–3.35) 0.156
99 0.44 (0.07–1.58) 0.64 (0.07–2.31) 0.132 0.39 (0.13–5.94) 0.48 (0.09–13.10) 0.366 0.42 (0.10–3.19) 0.53 (0.09–10.48) 0.091
100 0.26 (0.10–0.81) 0.37 (0.10–1.98) 0.019 0.30 (0.12–1.42) 0.37 (0.11–5.18) 0.128 0.27 (0.10–1.37) 0.37 (0.11–4.65) 0.008
28 0.10 (0.03–0.29) 0.13 (0.04–0.74) 0.030 0.12 (0.03–2.44) 0.17 (0.05–0.68) 0.099 0.10 (0.03–2.19) 0.15 (0.05–0.71) 0.005
66 0.04 (0.01–0.25) 0.08 (0.01–0.26) 0.0001 0.03 (0.01–1.38) 0.032 (0.01–0.19) 0.451 0.03 (0.01–0.57) 0.05 (0.01–0.25) 0.002
154 0.04 (0.01–0.13) 0.09a (0.00–0.18) 0.0001 0.04 (0.02–0.18) 0.04 (0.02–0.54) 0.536 0.04 (0.01–0.17) 0.05 (0.01–0.50) 0.001
Sum of all 14 (ng/L) 83.4 (29.2–396.9) 119.3 (34.6–757) 0.009 163.2 (17.7–1308.5) 119.2 (64.3–2657.4) 0.581 104.2 (26.1–1188.4) 119.3 (36.4–1785.1) 0.046
aOne unmeasurable sample.* Adjusted for maternal age, BMI, parity, and date of childbirth, for the combined data also for country of origin. was not signiﬁcantly correlated with the sum
of PBDE congeners (data not shown).
The date of childbirth within the cohort
was signiﬁcantly correlated in the Danish pla-
centas with the concentration of BDE-66 (r =
–0.246, p < 0.001), and in the Finnish pla-
centas with BDE-85 (r = 0.239, p < 0.01) and
BDE-153 (r = 0.275, p < 0.003).
There was no signiﬁcant difference in the
placenta concentration of the ﬁve most preva-
lent PBDEs between cryptorchid boys and
healthy boys in Denmark (p = 0.10–0.976) or
Finland (p = 0.09–0.835) or for their sum
(p = 0.312 and p = 0.128, respectively). The
results remained nonsigniﬁcant if prematurity
and SGA were included in the model. There
were no correlations between placental
PBDEs and serum reproductive hormones in
3-month-old infants.
Paired samples. The median concentra-
tions (nanograms per gram fat) of the 14 con-
geners in placenta were lower than the
concentration found in the paired breast milk
samples (n = 86) (Table 6), but there were
signiﬁcant correlations between the measure-
ments, except for BDE-85 and BDE-138.
The sum of all congeners in milk was
3.39 (95% CI, 1.43–48.2) for boys with
cryptorchidism and 3.15 (95% CI,
1.07–24.9) for controls (p = 0.228), and in
placenta 1.22 (95% CI, 0.64–9.32) for boys
with cryptorchidism and 1.17 (95% CI,
0.49–5.46) for controls (p = 0.871). Infant
reproductive hormones at 3 months of age
(27 Danish, 35 Finnish boys) were not corre-
lated to PBDE concentrations in placenta or
milk in this data subset.
Discussion
To our knowledge, this is the first study
describing an association between congenital
cryptorchidism in humans and exposure to
PBDEs. An association was found for the sum
of seven PBDEs (BDEs 47, 153, 99, 100, 28,
66, 154) in breast milk as well as for the indi-
vidual congeners BDEs 47, 100, 28, 66, and
154. Concentrations of BDEs 47, 100, and
154 were also positively correlated with
increasing serum LH values. This suggested
that a higher gonadotropin drive was neces-
sary to ensure normal testosterone production
by the Leydig cells (Suomi et al. 2006), and
thus a subtle primary testicular disfunction.
In this study we assessed infant exposure
by measuring the concentration of PBDEs in
breast milk, which reflects the accumulated
Flame retardants and cryptorchidism
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Figure 1. Sum of the 7 most prevalent PBDEs in
breast milk samples (BDEs 47, 153, 99, 100, 28, 66,
154, log-transformed values) from Denmark and
Finland in boys with cryptorchidism (n = 62, blue)
and healthy boys (n = 68, white). The box plot shows
medians and interquartile ranges. 
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Table 4. Seven less-prevalent PBDEs in breast milk samples from Danish and Finnish boys with and without cryptorchidism.
PBDE congener Denmark Finland
(ng/g fat) Control (n = 36) % Cryptorchid (n = 29) % Control (n = 32) % Cryptorchid (n = 33) %
Sum of 14 congeners 3.27 (1.11–9.12) — 4.27 (1.34–19.10) — 3.11 (1.04–29.5) — 4.27 (1.43–56.44) —
183 0.05 (0.0–0.58) 78 0.05 (0.0–0.23) 62 0.0 (0.0–0.17) 44 0.0 (0.0–0.49) 27
85 0.005 (0.0–0.05) 67 0.07 (0.0–0.22) 97 0.0 (0.0–0.12) 6 0.0 (0.0–0.08) 36
75 0.001 (0.0–0.01) 61 0.0 (0.0–0.01) 28 0.0 (0.0–0.06) 34 0.0 (0.0–0.03) 36
77 0.001 (0.0–0.03) 53 0.01 (0.0–0.04) 65 0.0 (0.0–0.12) 19 0.0 (0.0–0.02) 15
119 0.0 (0.0–0.01)  25 0.0 (0.0–0.01) 48 0.0 (0.0–0.02) 12 0.0 (0.0–0.01) 15
138 0.0 (0.0–0.02) 28 0.0 (0.0–0.03) 28 0.0 (0.0–0.01) 3 — 0
Concentrations are given as median (2.5th–97.5th percentiles). Percentages are of detectable samples. BDE-71 was not detected in any sample.
Figure 2. Concentration (percentiles) of the sum of all PBDEs, BDE-47, and BDE-100 (ng/g fat) in human
breast milk samples from Denmark (n = 65) and Finland (n = 65), 1997–2001. Note the differences in
absolute values in the y-axis.
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Healthy boysbody burden of the mother (Inoue et al.
2006; Jensen and Slorach 1991; Waliszewski
et al. 2001). It also is a proxy for prenatal fetal
exposure because PBDEs, especially the lower
brominated compounds, can cross the pla-
centa (Bi et al. 2006; Mazdai et al. 2003) and
are transferred to breast milk during lactation
(Darnerud and Risberg 2006). However,
when we assesssed exposure by measuring
PBDE in placenta, the results did not support
the above findings, despite the fact that 86
mother–child pairs were represented with
both milk and placenta samples. At present, it
is not clear why this is the case.
The concentration of all PBDE congeners
per gram fat in placenta was considerably
lower than in milk, and more congeners were
nondetectable. These differences did not have
any remarkable inﬂuence on analytical errors,
because the amount of fat used for analysis
was similar for placentas and milk samples. In
theory, placenta should be a better proxy for
fetal exposure than breast milk, because it
represents the direct route of chemical trans-
fer during pregnancy. The number of placen-
tas analyzed in this study was larger than the
number of milk samples, and should thus bet-
ter represent the pool of cases and controls.
We could not establish any obvious selection
bias of milk donors. On the other hand, due
to higher concentrations, milk analyses were
somewhat more reliable toward the lower end
of concentration. This should not be impor-
tant, because the main group differences were
seen at the higher end of PBDE concentra-
tions. It is currently unknown whether
PBDEs accumulate in placenta, but our
paired samples indicated that this may not be
the case. We found positive correlations
between measurements in placenta and breast
milk, but three to four times lower absolute
concentrations in placenta. Placenta concen-
trations may resemble measurements in single
blood samples, and thus reﬂect the situation
at delivery but not the long-term exposure.
There is some controversy as to whether
the placental transport of PBDEs may differ
between lower and higher brominated
PBDEs. An American study reported a strong
correlation of lipid-adjusted BDE concentra-
tions in maternal serum at term and cord
blood (Mazdai et al. 2003), whereas studies
from countries with a generally lower exposure
level found weaker correlations and higher val-
ues in maternal than in fetal samples (Bi et al.
2006). Segregation from serum into breast
milk samples did not always follow a 1:1 pat-
tern. The congener distribution appeared to
be similar for lower brominated BDEs (Bi
et al. 2006; Mazdai et al. 2003), whereas
higher brominated BDEs such as BDE-209
were 10 times higher in serum than in breast
milk (Inoue et al. 2006). Thus, the relative
distribution of congeners between placenta
and breast milk may also depend on the fat
composition of these two matrices causing dif-
ferent solubility. We found significantly
higher fat concentrations in the Finnish than
in the Danish samples, which may reflect
dietary habits in the two countries, because
both long-term and short-term diet as well as
the nutritional status may influence content
and composition of breast milk lipids (Ortiz-
Olaya et al.1996).
Current knowledge about human repro-
ductive health consequences after exposure to
PBDEs is very limited (Agency for Toxic
Substances and Disease Registry 2004). A
study from Taiwan showed an association
between the sum of 12 PBDE congeners in
breast milk, 10 of which were the same as in
our study, and lower birth weight and length
(Chao et al. 2007). Recently, a Swedish
case–control study found higher values of
PBDEs (sum of BDEs 47, 153, and 99) in
blood samples from mothers of young men
with testicular cancer than in age-matched
controls (Hardell et al. 2006). However,
maternal PBDE exposure was assessed 15–25
years after the critical time period—that is, at
the time of the cancer diagnosis—which con-
siderably weakens the possibility to establish a
causal link between exposure and outcome.
Also in this study (Hardell et al. 2006), expo-
sures to other persistent chemicals occurred
simultaneously, and it cannot be determined
how these substances interact in their effect
on reproductive development. Testicular can-
cer is the most severe clinical symptom of the
Main et al.
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Table 5. PBDEs in placentas from Danish and Finnish boys with and without cryptorchidism [median (2.5th–97.5th percentiles)].
PBDE congener Denmark Finland
(ng/g fat) Control (n = 129) % Cryptorchid (n = 39) % Control (n = 56) % Cryptorchid (n = 56) %
47 0.39 (0.19–1.64) 100 0.40 (0.20–2.17) 100 0.60 (0.12–6.19) 100 0.52 (0.12–4.07)  100
153 0.44 (0.20–1.21) 100 0.41 (0.21–0.98) 100 0.20 (0.08–0.92) 100 0.20 (0.10–0.53) 100
99 0.23 (0.10–0.99) 100 0.18 (0.13–0.68) 100 0.19 (0.04–1.57) 100 0.14 (0.04–1.20) 100
100 0.11 (0.05–0.40) 100 0.10 (0.06–0.56) 100 0.11 (0.03–0.79) 100 0.10 (0.04–0.68) 100
28 0.03 (0.01–0.06) 100 0.03 (0.01–0.40) 100 0.04 (0.01–0.52) 100 0.04 (0.01–0.12) 100
Sum of 5 congeners 1.28 (0.59–3.26) 100 1.13 (0.79–4.45) 100 1.16 (0.35–9.65) 100 1.05 (0.35–6.51) 100
66 0.0 (0.0–0.03) 29 0.0 (0.0–0.04) 38 0.01 (0.0–0.20) 64 0.01 (0.0–0.04) 62
154 0.0 (0.0–0.03) 39 0.0 (0.0–0.02) 5 0.01 (0.0–0.10) 79 0.0 (0.0–0.09) 34
183 0.0 (0.0–0.14) 26 0.0 (0.0–0.09) 10 — 0 0.0 (0.0–0.07) 5
85 0.0 (0.0–0.01) 2 — 0 0.0 (0.0–0.08) 25 0.0 (0.0–0.04) 34
75 (0.003) 1 — 0 — 0 — 0
77 — 0 — 0 0.0 (0.0–0.02) 4 — 0
119 0.0 (0.0–0.002) 3 — 0 — 0 (0.01) 2
138 — 0 — 0 0.0 (0.0–0.02) 2 — 0
Sum of 14 congeners 1.31 (0.61–3.31) 1.13 (0.79–4.48) 1.18 (0.35–9.89) 1.06 (0.36–6.67)
BDEs 153, 99, 100, and 28 were detected in all samples. BDE-71 was not detected in any sample. Percentages are of detectable samples. 
Table 6. Correlations between PBDE measurements in paired placenta and breast milk samples (ng/g fat) of
43 Danish and 43 Finnish boys [median (95% CI).
PBDE congener Median placenta Median milk rp -Value
28 0.03 (0.02–0.39) 0.12 (0.03–1.85) 0.73 0.0001
47 0.42 (0.19–2.84) 1.27 (0.45–14.7) 0.64 0.0001
66 0.0 (0.0–0.06) 0.04 (0.01–0.27) 0.31 0.004
71 0.0 (0.0–0.0) 0.0 (0.0–0.0) — —
75 0.0 (0.0–0.0) 0.0 (0.0–0.02) 0.21 0.057
77 0.0 (0.0–0.004) 0.0 (0.0–0.03) 0.30 0.006
85 0.0 (0.0–0.06) 0.0 (0.0–0.12) –0.02 0.823
99 0.19 (0.06–1.30) 0.42 (0.09–5.27) 0.55 0.0001
100 0.11 (0.05–0.43) 0.29 (0.10–1.41) 0.74 0.0001
119 0.0 (0.0–0.0) 0.0 (0.0–0.01) — —
138 0.0 (0.0–0.0) 0.0 (0.0–0.02) –0.05 0.664
153 0.32 (0.11–0.93) 0.85 (0.27–3.11) 0.81 0.0001
154 0.0 (0.0–0.09) 0.04 (0.01–0.18) 0.26 0.015
183 0.0 (0.0–0.18) 0.02 (0.0–0.38) 0.26 0.015
Sum  1.19 (0.59–6.11) 3.23 (1.16–27.6) 0.66 0.0001
Due to nondetectable levels, correlations could not be computed for BDE-71 and BDE-119. testicular dysgenesis syndrome (TDS), which
also encompasses impaired semen quality,
congenital cryptorchidism, and hypospadias
(Skakkebæk et al. 2001). TDS may be caused
by genetic, hormonal, or environmental fac-
tors (Sharpe 2006; Skakkebæk et al. 2001).
Prenatal exposure to PBDEs may have an
adverse effect on testicular growth and differ-
entiation in utero.
In animal studies, penta-brominated
PBDEs showed antiandrogenic activity (Stoker
et al. 2005). A peripubertal single-dose expo-
sure to a commercial mixture of penta-BDEs
delayed the onset of puberty in male and
female rats (Stoker et al. 2004) and suppressed
the growth of the seminal vesicles and ventral
prostate. In adult rats, a single-dose exposure
significantly increased LH concentration in
serum (Stoker et al. 2005). Our observation of
an association between PBDE levels in breast
milk and serum LH in infants at 3 months of
age is in line with these animal data.
Gestational exposure of rats to BDE-99 caused
a shortening of the anogenital distance in male
and female rats, reduction in primordial and
secondary ovarian follicles, a lower sperm
count, and lower estradiol and testosterone lev-
els in adulthood (Kuriyama et al. 2005;
Lilienthal et al. 2006). In vitro assays showed a
competitive androgen receptor binding for
BDEs 47, 99, and 100. BDEs 47, 71, and 100
inhibited dihydrotestosterone-induced tran-
scriptional activity (Stoker et al. 2005).
Because testicular descent is highly androgen-
dependent (Toppari 2003), the adverse effect
of PBDE on testicular descent could be caused
by their antiandrogenic properties.
In addition, BDEs 47, 100, 75, and 51,
particularly their hydroxylated metabolites,
are weakly estrogenic, and BDEs 153, 166,
and 190 are antiestrogenic in vitro (Legler and
Brouwer 2003; Meerts et al. 2001). Exposure
of female rats to BDE-99 led to the formation
of abundant vesicles and vacuolization of the
ovary (Talsness et al. 2005), which showed
signs of compromised steroidogenesis.
Prenatal female exposure to BDE-99 in rats
affected estrogen target genes in the uterus
(Ceccatelli et al. 2006). Thus, the delicate bal-
ance between androgens and estrogens in the
fetus may become altered by PBDE exposure.
In mice, the metabolism of BDE-47 was
highly dependent on the developmental stage
of the animal, being slowest in pups (Staskal
et al. 2006). Whether this also plays a role for
human fetal development is currently
unknown. Most exposure doses used in ani-
mal studies are several orders of magnitude
higher than the levels of PBDEs found in
breast milk in our study. However, there is
emerging evidence that also low-dose expo-
sure to, for example, BDE-99 close to levels
found in human adipose tissue may have an
adverse effect on the reproductive health of
the offspring (Anonymous 2005; Kuriyama
et al. 2005).
The distribution pattern of BDE con-
geners in breast milk corresponded to the dis-
tribution of BDE congeners in commercially
available mixtures of PBDEs (Alaee et al.
2006; Darnerud et al. 2001; Law et al. 2006;
Lilienthal et al. 2006). The absolute concen-
trations found in our study are within the
same order of magnitude as reported from
other Nordic and European countries
(Jaraczewska et al. 2006; Kalantzi et al. 2004;
Lind et al. 2003; Strandman et al. 2000) as
well as China (Bi et al. 2006) and Japan
(Eslami et al. 2006; Inoue et al. 2006). There
are, however, significant geographic differ-
ences between and within these countries,
which point toward differences in general
contamination levels. In our study, the total
amount of PBDEs did not differ between
Finnish and Danish milk or placenta samples,
but the pattern of congener distribution var-
ied, which indicated different sources and
timing of exposure. PBDE levels reported
from American studies of breast milk appear
to be considerably higher (Betts 2002). In
contrast, the previous exponential increase in
penta-PBDEs in Swedish breast milk samples
since the 1970s has reversed since the late
1990s (Law et al. 2006; Meironyte et al.
1999; Sjödin et al. 2003), when penta-BDEs
were gradually phased out. The collection of
breast milk samples in our study covered a
5-year period, and we found a negative corre-
lation between the level of PBDEs in breast
milk and the infant date of birth. This is in
line with the expected decline in the use of
penta-PBDEs in the two regions. The high
variability in PBDE concentrations among
individual mothers has been described also for
other human matrices (McDonald 2002),
and may reflect variability in both exposure
and metabolism. Deca-BDE can be converted
through sunlight exposure into lower bromi-
nated BDEs, which are more readily absorbed
from the intestine and bioaccumulate due to
their longer half-life than deca-BDE
(Watanabe and Tatsukawa 1987). However,
it is as yet unknown how much this process
contributes to human environmental expo-
sure to lower brominated PBDEs.
Exposure to PBDEs cannot explain the
observed geographic difference in the preva-
lence of cryptorchidism between Denmark
and Finland. Breast milk contains signiﬁcant
levels of other persistent and nonpersistent
chemical compounds (Damgaard et al. 2006;
Main et al. 2006a), which can affect perinatal
testicular development. Mothers with high
levels of PBDE exposure also may be exposed
to high levels of other persistent chemicals.
Thus, the combined exposure to multiple
environmental factors may cause the associa-
tion between congenital cryptorchidism and
PBDE concentration in breast milk (Koppe
et al. 2006). In addition, other lifestyle factors
and genetic susceptibility may play a role
(Damgaard et al. 2007; Sharpe 2006;
Virtanen et al. 2006). In our total study popu-
lation, the geographic difference in the preva-
lence of cryptorchidism was observed mainly
for mild forms of undescended testes, which
had a high degree of spontaneous postnatal
descent (Boisen et al. 2004). This pattern was
also seen in this subpopulation, in which
PBDEs was analyzed. However, also mild and
transient forms of cryptorchidism are associ-
ated with a subtle impairment of primary
testicular function (Suomi et al. 2006).
In conclusion, we used two different bio-
logical matrices in this study to assess infant
perinatal exposure. Breast milk, but not pla-
centa, showed an association with congenital
cryptorchidism. There are valid arguments for
either matrix, and risk assessment will require
more scrutiny. The association between PBDE
contamination levels in breast milk and con-
genital cryptorchidism is still of concern
because exposure to PBDEs is considerable in
some areas.
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